

## IN THE UNITED STATES PATENT &amp; TRADEMARK OFFICE

In re Appl.: Rakoczy, et al.. : Group Art Unit: 1635  
Serial No: 09/065,082 : Appl. Ref. No: GRI-010  
Filed: July 16, 1998 : Examiner: S. McGarry  
Title: **HYALURONIC ACID AS DNA CARRIER FOR GENE THERAPY  
AND VEGF ANTISENSE DNA TO TREAT ABNORMAL RETINAL  
VASCULARIZATION**

COVER LETTER

U.S. Patent and Trademark Office  
International Preliminary Examining Authority  
BOX PCT  
Washington, D.C. 20231


Sir/Madam:

In response to the Office Action dated March 15, 2000, enclosed for filing are the following:

1. (Revised) Declaration for Sequence Listing
2. Postcard

Respectfully submitted.

ARTER & HADDEN



Viviana Amzel, Ph. D.

Reg. No. 30930

Attorney for Applicant(s)

Date: \_\_\_\_\_

Citicorp Building  
725 South Figueroa Street  
Los Angeles, California 90017  
213-430-3520 Direct Ph.  
213-617-9255 Fax

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington D C 20231 on 3-21-00 by Jenny R. Wilson.

  
SIGNATURE

RECEIVED  
APR - 7 2000  
1600 MAIL ROOM

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rakoczy et al. : Appl. Ref.: GRI-010  
Serial. No: 09/065,082 : Examiner: S. McGarry  
Filing Date: 3 Aug. 1999 : Group Art Unit: 1635  
For: **HYALURONIC ACID AS DNA CARRIER FOR GENE THERAPY AND VEGF  
ANTISENSE DNA TO TREAT ABNORMAL RETINAL VASCULARIZATION**

#16  
M.G.  
4/8/00


DECLARATION

Assistant Commissioner of Patents & Trademarks  
Washington, DC 20231

Sir/Madam:

I, Viviana Amzel, hereby state that the contents of the paper and computer readable copies of the enclosed Sequence Listing section submitted on February 2, 2000 and of the sequences contained in the originally filed US patent application, the Australian and PCT priority applications, and the amendments made with the responses filed in the PCT phase (copies were enclosed with the papers filed with documents at the time of entering the US National Phase) are the same. The enclosed Sequence Listing (paper and computerized forms) include no new matter and the sequences therein, to the best of applicant's knowledge, are the same as the sequences in the original Australian, PCT and US patent applications as filed, and the amendments entered during the PCT phase.

Respectfully submitted.  
ARTER & HADDEN

  
Viviana Amzel, Ph. D.  
Agent for Applicant

RECEIVED  
APR - 7 2000  
1600 MAIL ROOM

Citicorp Building  
725 South Figueroa St.  
Suite 3400  
213-430-3520 Ph.  
213-617-9255 Fax

I hereby certify that this paper or fee is being deposited with the United States Postal Service "First Class Mail" service under 37 CFR 1.8 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington DC 20231, on March 21, 2000, by Jenny Rebecca Wilson.

  
SIGNATURE